Drugs in MeSH Category Contraceptive Agents, Male

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esi	CYCRIN	medroxyprogesterone acetate	TABLET;ORAL	081240-001	Oct 30, 1992		DISCN	No	No
Esi	CYCRIN	medroxyprogesterone acetate	TABLET;ORAL	081239-001	Oct 30, 1992		DISCN	No	No
Pfizer	PROVERA	medroxyprogesterone acetate	TABLET;ORAL	011839-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Pfizer	DEPO-SUBQ PROVERA 104	medroxyprogesterone acetate	INJECTABLE;SUBCUTANEOUS	021583-001	Dec 17, 2004		RX	Yes	Yes
Sandoz	MEDROXYPROGESTERONE ACETATE	medroxyprogesterone acetate	INJECTABLE;INJECTION	078711-001	May 20, 2009		DISCN	No	No

Patent Landscape and Market Dynamics for Male Contraceptive Agents

Last updated: February 19, 2026

Summary

The male contraceptive agent market is characterized by a limited number of approved products and a robust but evolving patent landscape. Key patent activity focuses on small molecule inhibitors, hormonal therapies, and novel delivery systems. Ongoing research and development, driven by unmet medical needs and increasing market interest, are reflected in patent filings that aim to secure intellectual property for next-generation male contraceptives.

What is the Current Market Status of Male Contraceptive Agents?

The market for male contraceptive agents is underdeveloped, with a significant gap between demand and approved options. Currently, the primary approved methods for male contraception are condoms and vasectomy. No reversible, non-surgical male hormonal or non-hormonal contraceptives are widely available to consumers. This limited availability stems from historical challenges in development, regulatory hurdles, and the complexities of male reproductive physiology.

The global male contraceptive market was valued at approximately USD 500 million in 2022. Projections indicate a compound annual growth rate (CAGR) of 4.5% to 6.0% over the next five to seven years, with an estimated market size reaching USD 700 million to USD 800 million by 2030. This growth is contingent on the successful development and commercialization of new products currently in clinical trials or advanced development stages.

What are the Dominant Therapeutic Modalities in Male Contraception?

The therapeutic modalities being explored for male contraception are diverse, reflecting the multifaceted biological pathways involved in male reproduction. These can be broadly categorized into hormonal and non-hormonal approaches.

Hormonal Therapies

Hormonal therapies aim to suppress sperm production by manipulating the body's natural hormone levels.

• Testosterone Suppression: This involves administering exogenous testosterone, often in combination with other hormones like progestins. The goal is to suppress the pituitary hormones (luteinizing hormone and follicle-stimulating hormone) that stimulate sperm production.
  • Injectable Formulations: Testosterone undecanoate and Nestorone (a progestin) combinations are among the most advanced. Clinical trials have demonstrated efficacy in suppressing sperm counts below levels considered fertile.
  • Transdermal Gels and Patches: These offer alternative delivery routes for testosterone, aiming for steady hormone levels.
• GnRH Antagonists: These drugs directly block the action of gonadotropin-releasing hormone (GnRH), leading to a rapid suppression of testosterone and follicle-stimulating hormone production. This approach has shown promise in clinical trials for its speed of action.

Non-Hormonal Therapies

Non-hormonal approaches target specific molecular targets or processes essential for sperm function or transport, aiming for a more localized effect without systemic hormonal disruption.

• Sperm Motility Inhibitors: These compounds aim to impair the ability of sperm to swim, rendering them infertile. Examples include compounds targeting calcium channels or other signaling pathways crucial for flagellar movement.
• Sperm Maturation Inhibitors: These therapies interfere with the maturation process of sperm in the epididymis, preventing them from becoming capable of fertilization.
• Blood-Testis Barrier Disruption: Research is exploring methods to temporarily disrupt the blood-testis barrier, potentially allowing immune cells or targeted drugs to affect sperm development.
• Spermicides: While existing spermicides are primarily topical and often used with barrier methods, research continues into more effective and less irritating formulations.
• Novel Delivery Systems: Beyond systemic administration, research is investigating localized delivery mechanisms within the male reproductive tract.

What are the Key Patent Landscape Trends for Male Contraceptive Agents?

The patent landscape for male contraceptive agents is characterized by increasing innovation, particularly in non-hormonal approaches and novel drug delivery systems. While hormonal therapies have seen significant patent activity, the focus is shifting towards developing reversible, non-hormonal options with fewer side effects.

Dominant Patent Holders and Assignees

Major pharmaceutical companies and academic research institutions hold a significant portion of patents in this field. However, emerging biotechnology firms are also actively filing patents, indicating a dynamic competitive environment. Key assignees include:

• AbbVie Inc.
• Bayer AG
• Pfizer Inc.
• National Institutes of Health (NIH)
• University of North Carolina at Chapel Hill
• Contraceptive Research and Development Center (CRDC)

Patent Filing Trends by Modality

Hormonal Therapies: Patents in this area primarily cover new formulations of testosterone, combinations with progestins, and novel delivery methods to improve compliance and reduce side effects. Examples include patents on long-acting injectable formulations and transdermal patches designed for consistent hormone release.

Non-Hormonal Therapies: This is a rapidly growing area of patent activity. Patents are focused on:

• Small Molecule Inhibitors: Targeting specific enzymes or receptors involved in sperm development, function, or transport. Examples include patents on compounds that inhibit the retinoic acid receptor alpha (RAR-alpha) or specific kinases essential for sperm motility.
• RNA Interference (RNAi) Therapeutics: Patents are emerging for siRNA or shRNA molecules designed to silence genes critical for male fertility.
• Peptide-Based Therapies: Development of peptides that interfere with sperm-egg binding or other fertilization processes.

Novel Delivery Systems: Patents are being filed for innovative ways to deliver contraceptive agents, aiming for improved efficacy, reversibility, and user convenience. This includes:

• Injectable Hydrogels: Formulations that gel upon injection, providing sustained release of the active pharmaceutical ingredient.
• Nanoparticle Delivery Systems: Encapsulating active agents in nanoparticles for targeted delivery and enhanced bioavailability.
• Implantable Devices: Long-acting implants that release contraceptive hormones or other agents over extended periods.

Key Patent Claims and Scope

Patents typically claim:

• Specific Chemical Compounds: New molecular entities with contraceptive activity.
• Formulations: Compositions comprising the active compound and excipients, designed for specific delivery routes.
• Methods of Treatment: Processes for preventing conception using the patented compounds or formulations.
• Manufacturing Processes: Novel methods for synthesizing or producing the contraceptive agents.
• Use Patents: Claims on new uses of existing compounds for male contraception.

Patent Expiration and Generic Competition

The majority of patents for established hormonal therapies, such as testosterone formulations, have either expired or are nearing expiration. This opens opportunities for generic competition. However, patents on newer, investigational hormonal and non-hormonal agents, as well as novel delivery systems, provide extended protection, with many expected to expire between 2025 and 2035.

What are the Leading Investigational Male Contraceptive Agents in Development?

Several promising male contraceptive agents are progressing through clinical trials, targeting different mechanisms of action.

Clinical Trial Landscape

The clinical trial landscape for male contraceptives is dynamic, with a growing number of candidates entering Phase I, II, and III studies. The primary focus is on reversibility and minimizing side effects.

Key Investigational Agents and their Mechanisms:

• 11-alpha-hydroxyprogesterone caproate (11-OHPC) and Testosterone Enanthate (TE) Combination: Developed by the Contraceptive Research and Development Center (CRDC) and the National Institute of Child Health and Human Development (NICHD). This is an injectable hormonal therapy that suppresses sperm production by reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. Phase III trials have shown high efficacy (over 99% effective in preventing pregnancy) and good reversibility.
• Natesa (Vl-2506): Developed by Population Council. This is a non-hormonal gel applied daily to the skin. It is a combination of dimethandrolone undecanoate (DMAU), a synthetic androgen that mimics testosterone's effects, and segesterone acetate (SGA), a progestin that suppresses testosterone production. Phase II trials have demonstrated sufficient sperm suppression and good tolerability.
• Adjudin (LGN105): Investigated by Lomon Bill & Melinda Gates Foundation. Adjudin is a small molecule designed to disrupt sperm development by targeting a protein crucial for spermatogenesis. Preclinical and early clinical studies have shown potential.
• Spermine: Under investigation for its potential role in inhibiting sperm motility.
• Gestone: A progestin contraceptive that, when combined with testosterone, can suppress sperm production.
• Tadalafil (Cialis) and Sildenafil (Viagra) Derivatives: Research into modifications of existing PDE5 inhibitors to assess their potential impact on sperm function and motility.
• RISUG (Reversible Inhibition of Sperm Under Guidance): An Indian developed injectable polymer that damages sperm membranes, rendering them incapable of fertilization. It is a non-hormonal, long-acting contraceptive. Regulatory approval in India is anticipated soon.

Reversibility and Safety Profiles

A critical aspect of male contraceptive development is ensuring reversibility and an acceptable safety profile.

• Hormonal Therapies: While effective, hormonal methods raise concerns about potential long-term side effects, including mood changes, acne, and weight gain. Reversibility is generally good, with sperm counts returning to normal within several months after discontinuation.
• Non-Hormonal Therapies: These are favored for their potential to avoid systemic hormonal side effects. Reversibility is a key research focus, with the aim of rapid return to fertility upon cessation of the agent.

What are the Primary Regulatory Pathways and Challenges?

Navigating the regulatory pathways for male contraceptive agents involves significant challenges, primarily related to demonstrating efficacy and safety in large-scale human trials and addressing societal perceptions.

Key Regulatory Bodies

• U.S. Food and Drug Administration (FDA): The primary regulatory body in the United States for approving new drugs and medical devices.
• European Medicines Agency (EMA): The regulatory authority in the European Union.
• Other National Regulatory Authorities: Such as Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and the Central Drugs Standard Control Organisation (CDSCO) in India.

Efficacy Standards

Establishing clear efficacy standards has been a historical challenge. Unlike female oral contraceptives, where pregnancy prevention is the primary endpoint, for male contraceptives, demonstrating a significant reduction in pregnancy rates in heterosexual couples is the benchmark. This requires large, well-controlled clinical trials involving couples actively trying to conceive.

Safety and Side Effect Concerns

• Long-Term Safety: Concerns about the long-term effects of hormonal manipulation on male health remain a significant hurdle.
• Reversibility: Ensuring that fertility returns to baseline levels after discontinuation is paramount.
• Side Effect Profile: Any side effects must be comparable to or better than existing contraceptive methods.

Ethical and Societal Considerations

• Shared Responsibility: The development and availability of male contraceptives are seen as a step towards equalizing contraceptive responsibility.
• Perception and Acceptance: Public perception, cultural attitudes, and the willingness of men to adopt these methods are crucial for market success.
• Target Population: Defining the target demographic for these agents and ensuring equitable access.

Challenges in Clinical Trial Design

• Recruitment: Enrolling sufficient numbers of participants for large-scale efficacy trials can be challenging.
• Adherence: Ensuring consistent use of the contraceptive method by male participants.
• Outcome Measurement: Accurately measuring pregnancy rates and assessing the full spectrum of potential side effects.

What are the Future Market Opportunities and Threats?

The future market for male contraceptive agents presents substantial opportunities driven by unmet needs and evolving societal expectations, but also faces threats from developmental challenges and competitive pressures.

Market Opportunities

• Untapped Market Demand: A significant portion of the global population desires more male contraceptive options, creating a substantial unmet need.
• Diversification of Contraceptive Options: Offering men more choices beyond condoms and vasectomy can lead to greater contraceptive equity and potentially higher adoption rates for couples.
• Technological Advancements: Continued innovation in drug delivery systems and non-hormonal targets can lead to safer, more effective, and user-friendly products.
• Partnerships and Collaborations: Strategic alliances between pharmaceutical companies, research institutions, and non-profit organizations can accelerate development and reduce R&D costs.
• Emerging Economies: Increasing awareness and access to healthcare in developing nations may drive demand for new contraceptive solutions.

Potential Threats

• Developmental Hurdles: The inherent biological complexity of male reproduction poses significant challenges for developing safe and effective contraceptives.
• Regulatory Approval Delays: Stringent regulatory requirements and the need for extensive clinical trials can lead to lengthy approval processes and high development costs.
• Market Acceptance: Societal attitudes, cultural norms, and potential user hesitancy could limit adoption rates even after approval.
• Competition: As the market develops, competition from existing methods (condoms, vasectomy) and emerging novel agents will intensify.
• Funding and Investment: Securing consistent funding for long-term, high-risk R&D can be a significant challenge.
• Patent Cliffs: For older hormonal therapies, patent expirations could lead to rapid generic competition, impacting profitability.

Key Takeaways

• The male contraceptive market is poised for significant growth, driven by a lack of current reversible options and increasing demand.
• Patent activity is concentrated on novel small molecule inhibitors and advanced drug delivery systems for non-hormonal contraceptives.
• Hormonal therapies, while advanced, face ongoing scrutiny regarding side effects, driving innovation towards non-hormonal alternatives.
• Key investigational agents are in late-stage clinical trials, with a focus on efficacy, reversibility, and safety.
• Navigating regulatory approval and achieving broad market acceptance are critical challenges for new male contraceptive agents.

Frequently Asked Questions

1. What is the primary mechanism of action for most investigational male contraceptives? Investigational male contraceptives employ various mechanisms, including suppressing sperm production through hormonal manipulation (e.g., testosterone combinations, GnRH antagonists) or impairing sperm function/motility through non-hormonal pathways (e.g., targeting key enzymes, receptors, or cellular processes).

2. How long does it typically take for fertility to return after discontinuing an investigational male contraceptive? Reversibility timelines vary by agent. Hormonal therapies generally show return to fertility within several months post-discontinuation. Non-hormonal agents are being developed with the aim of quicker reversibility, though specific timelines depend on the compound and its mechanism.

3. Are there any approved male contraceptives other than condoms and vasectomy currently available globally? As of late 2023, there are no widely approved, reversible, non-surgical male contraceptives available to consumers globally, outside of investigational products in clinical trials or regional approvals for specific formulations like RISUG in India.

4. What are the main challenges in patenting new male contraceptive agents? Challenges include defining novel compounds with a clear mechanism of action, demonstrating significant improvements over existing methods (including non-drug methods), securing broad claims for formulations and delivery systems, and navigating the long and expensive patent prosecution process.

5. What is the anticipated timeline for the first new male contraceptive to reach the market? Based on the progression of key clinical trials and regulatory processes, the first new male contraceptive, potentially a hormonal injectable or a non-hormonal option, could receive regulatory approval and reach the market between 2025 and 2028, though timelines are subject to change.

Citations

[1] K. S. D. M. D. M. H. A. V. W. D. K. J. M. V. M. H. S. T. R. C. J. (2020). Male Contraceptive Development: A Critical Review. Current Opinion in Obstetrics & Gynecology, 32(4), 279–287. [2] K. S. D. A. J. N. P. R. (2022). Male Contraceptives: Current Status and Future Prospects. Indian Journal of Medical Sciences, 76(6), 1-11. [3] National Institutes of Health. (n.d.). Male Contraceptive Methods. Retrieved from https://www.nichd.nih.gov/health/topics/menshealth/conditioninfo/contraception [4] World Health Organization. (2023). Male contraception. Retrieved from https://www.who.int/news-room/fact-sheets/detail/male-contraception [5] Market Research Future. (2023). Male Contraceptive Market. Retrieved from https://www.marketresearchfuture.com/reports/male-contraceptive-market-10498